ArticleCureus2025
Unmasking Epstein-Barr Virus (EBV)-Positive Large B-Cell Lymphoma as an Underlying Trigger in a Post-COVID Hemophagocytic Lymphohistiocytosis Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome caused by dysregulated activation of cytotoxic T cells and macrophages, most commonly triggered by infection or malignancy. We describe a 79-year-old male with a remote history of multiple malignancies, all in remission, who presented with persistent fevers and was found to have pancytopenia and transaminitis following a COVID-19 infection two weeks earlier. An elevated H-score prompted early bone marrow biopsy, which confirmed hemophagocytosis and revealed a smoldering Epstein-Barr virus (EBV)-positive large B-cell lymphoma as the likely underlying trigger. Initiation of dexamethasone monotherapy led to rapid clinical and laboratory improvement before definitive chemotherapy for lymphoma was considered. This case highlights the "threshold model" of HLH, in which compounding insults such as COVID-19 infection and occult EBV-positive lymphoma can breach the immunologic tipping point. It also underscores the importance of maintaining a high index of suspicion for rare but life-threatening conditions such as HLH. Prompt H-score calculation and bone marrow sampling can secure the diagnosis, uncover the underlying trigger, and expedite appropriate therapy in patients with HLH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.